The most common adverse events associated with sacral neuromodulation include pain at implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations. Any of these may require additional surgery or cause return of symptoms.

**INTERSTIM™ MICRO SYSTEM RECHARGE WITHOUT LIMITS**

**OVERDRIVE™ BATTERY TECHNOLOGY**

**NOT ALL BATTERIES ARE CREATED EQUAL**

The InterStim™ Micro device is:

**SMALLER**
- At 2.8 cm³, the InterStim™ Micro neurostimulator is the smallest sacral neuromodulation device on the market
- 49% smaller than the Axonics® r-SNM neurostimulator*

**BETTER**
- Zero battery fade at 15 years†

**FASTER**
- Rapid recharging
  - Recharge in 20 minutes, once a week**
  - Recharge from zero to 100% in less than an hour‡

**STRONGER**
- Patients can charge how and when they want, whether for a full cycle or just topping off
- The recharger doesn’t need to be perfectly aligned for recharging to be successful

---

The most common adverse events associated with sacral neuromodulation include pain at implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations. Any of these may require additional surgery or cause return of symptoms.
Indications for Use:

Sacral Neuromodulation delivered by the InterStim™ system for Urinary Control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments.

The following Warning applies only to Sacral Neuromodulation for Urinary Control:

**Warning:** This therapy is not intended for patients with mechanical obstruction such as benign prostatic hypertrophy, cancer, or urethral stricture.

Sacral Neuromodulation delivered by the InterStim™ system for Bowel Control is indicated for the treatment of chronic fecal incontinence in patients who have failed or are not candidates for more conservative treatments.

Contraindications for Urinary Control and for Bowel Control: Diathermy. Patients who have not demonstrated an appropriate response to test stimulation or are unable to operate the neurostimulator.

Warnings/Precautions/Adverse Events:

- **For Urinary Control:** Safety and effectiveness have not been established for bilateral stimulation; pregnancy, unborn fetus, and delivery; pediatric use under the age of 16; or for patients with neurological disease origins.

- **For Bowel Control:** Safety and effectiveness have not been established for bilateral stimulation; pregnancy, unborn fetus, and delivery; pediatric use under the age of 18; or for patients with progressive, systemic neurological diseases.

- For Urinary Control and for Bowel Control: The system may be affected by or adversely affect cardiac devices, electrocautery, defibrillators, ultrasonic equipment, radiation therapy, MRI, theft detectors/screening devices. Adverse events include pain at the implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations, including jolting or shock sensations. Patients should be assessed preoperatively for the risk of increased bleeding. For full prescribing information, please call Medtronic at 1-800-328-0810 and/or consult Medtronic’s website at www.medtronic.com. Product technical manual must be reviewed prior to use for detailed disclosure.

USA Rx Only. Rev 0517

© 2020 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further. Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. UC20010815 EN